Moutih Rafei
Chief Tech/Sci/R&D Officer at DEFENCE THERAPEUTICS INC.
Net worth: 57 400 $ as of 30/05/2024
Moutih Rafei active positions
| Companies | Position | Start | End |
|---|---|---|---|
| DEFENCE THERAPEUTICS INC. | Director/Board Member | 04/01/2021 | - |
| Chief Tech/Sci/R&D Officer | 08/10/2020 | - | |
| University of Montréal | Corporate Officer/Principal | - | - |
Career history of Moutih Rafei
Former positions of Moutih Rafei
| Companies | Position | Start | End |
|---|---|---|---|
IntelliStem Technologies, Inc.
 IntelliStem Technologies, Inc. BiotechnologyHealth Technology IntelliStem Technologies, Inc. is a Canadian biotechnology company that specializes in engineering stem cells for the development of next-generation cell therapy products. The private company is based in Toronto, Canada. The company's proprietary cell platforms, including Super Sentinel Cells (SSCs) for cancer therapeutics and IntelliCells for drug discovery and target identification, are genetically engineered. IntelliStem is currently moving into human clinical trials. The company was founded by Riam Shammaa, who has been the CEO since incorporation. | Chief Tech/Sci/R&D Officer | - | 31/07/2023 |
| Founder | - | 31/07/2023 |
Training of Moutih Rafei
| McGill University | Doctorate Degree |
Statistics
International
| Canada | 5 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
| Director/Board Member | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| DEFENCE THERAPEUTICS INC. | Health Technology |
| Private companies | 1 |
|---|---|
IntelliStem Technologies, Inc.
IntelliStem Technologies, Inc. BiotechnologyHealth Technology IntelliStem Technologies, Inc. is a Canadian biotechnology company that specializes in engineering stem cells for the development of next-generation cell therapy products. The private company is based in Toronto, Canada. The company's proprietary cell platforms, including Super Sentinel Cells (SSCs) for cancer therapeutics and IntelliCells for drug discovery and target identification, are genetically engineered. IntelliStem is currently moving into human clinical trials. The company was founded by Riam Shammaa, who has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Moutih Rafei
- Experience
